(Circulation. 1999;99:3096-3098.)
© 1999 American Heart Association, Inc.
Brief Rapid Communications |
From the Laboratoire de Biochimie (S.V.-B., C.L., G.D., J.B.) and Département d'Anesthésie Réanimation (I.P., G.P., J.M.D.), Hôpital Bichat, Paris, France; INSERM U141 (E.V., D.H., B.I.L.), Hôpital Lariboisière, Paris, France; and INSERM SC7 (O.P.), Paris, France.
| Abstract |
|---|
|
|
|---|
Methods and ResultsThe protocol was performed in 68 patients undergoing coronary artery bypass grafting (n=33) or valve surgery (n=35) in whom mean arterial pressure decreased below 65 mm Hg during normothermic CPB. Under constant and nonpulsatile pump flow conditions (2 to 2.4 L · min-1 · m-2), a PE dose-response curve was generated by the cumulative injection of individual doses of PE (25 to 500 µg). The G894T polymorphism of the eNOS gene was determined, and 3 groups were defined according to genotype (TT, GT, and GG). Groups were similar with regard to perioperative characteristics. The PE dose-dependent response was significantly higher in the allele 894T carriers (TT and GT) than in the homozygote GG group (P=0.02), independently of possible confounding variables.
ConclusionsThese results evidenced an enhanced responsiveness to
-adrenergic stimulation in patients with the 894T allele in the
eNOS gene.
Key Words: nitric oxide endothelium genes receptors, adrenergic, alpha vasoconstriction
| Introduction |
|---|
|
|
|---|
1-adrenoceptor agonist commonly used in such
clinical settings to support stable hemodynamics.
However, experimental evidence shows differences in vascular reactivity
to PE during CPB that remain largely unexplained. The endothelium plays an important part in functional changes in the vasculature by releasing physiologically active substances that locally modulate arterial tone.1 Both under basal conditions and after agonist or mechanical stimulation, the endothelium releases relaxing factors such as nitric oxide (NO) or NO-containing molecules.2
In humans, a variant of the endothelial NO synthase
(eNOS) gene within exon 7 has been identified: G
T
transversion at nucleotide position 894 of eNOS
cDNA, resulting in a change of Glu298 (GAG) to Asp (GAT). A significant
association between the risk of coronary heart disease,
especially in vasospastic angina pectoris, and the eNOS
polymorphism has been found,3 which suggests that
the G894
T variant in the eNOS gene could affect vascular
coronary reactivity.
Because activation of eNOS induces the release of the potent
vasodilator NO, we hypothesized that the polymorphism of the
eNOS gene could be related to changes in responsiveness and
vascular reactivity to vasoactive agents. The aim of this work was to
determine a possible association between the G894
T polymorphism
in the eNOS gene and vascular responsiveness to
-adrenergic stimulation during cardiac surgery in patients requiring
vasoconstrictor therapy.
| Methods |
|---|
|
|
|---|
|
Anesthesia and CPB Management
Anesthesia was induced with high doses of fentanyl,
midazolam, and pancuronium bromide and maintained by repeated
injections of the same agents (Table 2
).
Normothermic nonpulsatile CPB and myocardial protection
were standardized for all patients.
|
PE Dose-Response Curve
Mean arterial pressure (MAP) was recorded
through a radial artery catheter. The transducer was maintained at the
midaxillary level.
Intraoperative parameters are shown in Table 2
.
Patients with extreme values of hematocrit (<20% and >35%), pH
(<7.4 and >7.6), PCO2 (<3.0 kPa
and >5.3 kPa), and temperature (<35°C) were excluded.
Within 30 minutes after the onset of CPB, after stabilization of temperature and biological parameters, baseline hemodynamic parameters were continuously recorded, and the protocol was performed when MAP decreased below 65 mm Hg for a pump flow ranging from 2 to 2.4 L · min-1 · m-2. The PE dose-response curve was then generated by injection of individual doses of PE, with a 2-minute interval between injections, until MAP reached a value of 85 mm Hg (in the following sequence of 25, 50, 75, 100, 150, 200, 250, and 500 µg). During PE injections, pump flow was maintained at a constant rate; no injection of anesthetic drugs was performed during this period.
Detection of the G to T Variation in the eNOS
Gene
Genotyping of all subjects was performed by polymerase chain
reaction amplification according to previously described
procedures.3 4
Data Analysis
Data were expressed as mean±SD and analyzed within
genotype groups by 2-way ANOVA or
2
test. Analyses of PE dose-response curves were performed only
for the 3 doses of PE that were administered in all patients (ie, 25,
50, and 75 µg). Comparisons of dose-response curves in GG versus GT
and TT patients were made by 2-way ANOVA between factors (ie,
genotypes) and within factor (ie, dose). An additional
analysis was made to ensure that the effect of genotype
was not due to confounding factors. For this purpose, a
multivariate regression analysis of the area
under the dose-response curve was performed, taking into account
genotype and main clinical variables (ie, age, sex,
previous myocardial infarction, hypertension, diabetes, treatments, and
type of surgery). Because of skewed statistical distribution of the
response, all analyses were performed after normalization of
the logarithmic transformation of this variable.
In all univariate tests, the significance level was fixed at 5%. For the multivariate regression analysis, the threshold F value to accept a variable in the model was fixed at 4.0, as suggested by Dixon.5 All tests were performed with the Biomedical data package (BMDP, from UCLA at Los Angeles, Calif).
| Results |
|---|
|
|
|---|
eNOS Genotypes
Among the 564 genotyped patients and in the 68 patients
requiring PE infusion during CPB, we reported similar allelic
frequencies of the 894T allele (0.48) and genotype
distribution in the TT, GT, and GG groups (11%, 40%, and 49% versus
10.8%, 40%, and 49.2%, respectively), in agreement with the
frequencies predicted by Hardy-Weinberg equilibrium
(
2=0.0017; P=NS).
Hemodynamic Study and PE Dose-Response
Curves
Initial MAP before PE administration was similar in the 3 groups
(54.1±6, 53.6±10, and 56.0±6 mm Hg in the TT, GT, and GG
groups, respectively). The PE dose-dependent response was significantly
higher in the allele 894T carriers (TT and GT) than in the
homozygote GG group (P=0.02). Moreover, in the TT group, no
patient needed a PE injection >150 µg to reach a MAP value of
85 mm Hg (Figure
). In
multivariate analysis, eNOS
genotype appeared as the only predictive variable of the
PE-response.
|
| Discussion |
|---|
|
|
|---|
In our conditions, MAP recorded in patients undergoing CPB was chosen as a marker for the vascular response to PE. Extracorporeal circulation provided a model of purely resistive vascular behavior, because pump flow can be controlled. Moreover, during nonpulsatile bypass, flow and pressure are primarily nonoscillatory, and the pressure-flow relationship is determined mainly by the vascular resistance.6
Initial MAP was similar in the 3 eNOS genotype
groups, ruling out an effect of the polymorphism of the
eNOS gene in measured basal blood pressure. Conversely, the
enhanced hemodynamic response to bolus PE found in
patients with the 894T allele, independently of
perioperative factors known to affect
-adrenergic
responsiveness in patients undergoing CPB,7 suggested
an association between the polymorphism of the eNOS gene
and the responsiveness to
-adrenergic stimulation.
Although our study does not identify any involved mechanism, we can hypothesize that the polymorphism of the eNOS gene could affect stimulated NO production. Thus, because in vivo and in vitro studies have demonstrated that the endothelium, by releasing NO, reduces the maximal response to PE,8 we can suggest a lesser production of NO in patients with the 894T allele. Although the G894T variant is not located in any functional consensus sequence, it could be involved in a conformation change in the eNOS protein, consequently inducing an alteration in the NO pathway.
Changes in endothelial function may have important clinical implications for the pathogenesis of cardiovascular disorders. Therefore, functional alterations of the endothelium-derived NO pathway, especially those involved in the pathogenesis of coronary spasm3 and hypertension,4 may be due to a lesser endothelial release of NO related to the presence of the 894T allelic form of the eNOS gene, as suggested by the present study.
In summary, this study reports the first evidence for an association
between the G894
T polymorphism in the eNOS gene and
enhanced vascular reactivity to PE in humans, suggesting that DNA
sequence differences in the eNOS gene may affect vascular
responsiveness and reactivity to
-adrenergic stimulation. However,
because the sample of the present study has been highly selected,
the sample size is less than in normal gene polymorphism
association studies. Thus, another independent study seems to be
necessary to verify our present finding. Furthermore, it remains to
be determined whether the G894T variant gives rise to direct functional
alterations of the endothelium-derived NO pathway or is
a genetic marker associated with some causal loci. Functional
analysis of the 894T variant and measurement of the NO
production must be performed to confirm the results of our
study.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received December 31, 1998; revision received April 16, 1999; accepted April 22, 1999.
| References |
|---|
|
|
|---|
2. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524526.[Medline] [Order article via Infotrieve]
3. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet. 1998;103:6569.[Medline] [Order article via Infotrieve]
4.
Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M,
Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K,
Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T,
Azuma N, Yoshimasa T, Itoh H, Masuda I, Yasue H, Nakao K.
Endothelial nitric oxide synthase gene is positively
associated with essential hypertension. Hypertension. 1998;32:38.
5. Dixon. BMDP Manual. Los Angeles, Calif: University of California Press Berkeley; 1992;1:387426.
6. Milnor WR. Hemodynamics. 2nd ed. Baltimore, Md: Williams & Wilkins; 1989:167203.
7. Johns RA. Endothelium, anesthetics, and vascular control. Anesthesiology. 1993;79:13811391.[Medline] [Order article via Infotrieve]
8.
Dohi Y, Thiel MA, Bühler FR, Lüscher TF.
Activation of endothelial L-arginine
pathway in resistance arteries: effect of age and hypertension.
Hypertension. 1990;16:170179.
This article has been cited by other articles:
![]() |
R. G. Dias, M.-J. N. N. Alves, A. C. Pereira, M. U. P. B. Rondon, M. R. dos Santos, J. E. Krieger, M. H. Krieger, and C. E. Negrao Glu298Asp eNOS gene polymorphism causes attenuation in nonexercising muscle vasodilatation Physiol Genomics, April 10, 2009; 37(2): 99 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Rao, L. Zhang, and D. T. O'Connor Complex Trait Genetics: The Role of Mechanistic "Intermediate Phenotypes" and Candidate Genetic Loci J. Am. Coll. Cardiol., July 8, 2008; 52(2): 166 - 168. [Full Text] [PDF] |
||||
![]() |
C. D. Mazer, F. Briet, K. R. Blight, D. J. Stewart, M. Robb, Z. Wang, A. M. Harrington, W. Mak, X. Li, and G. M.T. Hare Increased cerebral and renal endothelial nitric oxide synthase gene expression after cardiopulmonary bypass in the rat J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 13 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Yates and M. Stafford-Smith The genetic determinants of renal impairment following cardiac surgery. Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 314 - 326. [Abstract] [PDF] |
||||
![]() |
J. P. Casas, G. L. Cavalleri, L. E. Bautista, L. Smeeth, S. E. Humphries, and A. D. Hingorani Endothelial Nitric Oxide Synthase Gene Polymorphisms and Cardiovascular Disease: A HuGE Review Am. J. Epidemiol., November 15, 2006; 164(10): 921 - 935. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Proctor, K. L. Dreher, S. E. Kelly, and J. C. Russell Hypersensitivity of Prediabetic JCR:LA-cp Rats to Fine Airborne Combustion Particle-Induced Direct and Noradrenergic-Mediated Vascular Contraction Toxicol. Sci., April 1, 2006; 90(2): 385 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang and X.-F. Ming Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., March 1, 2006; 4(1): 53 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M Vivian Should Drug Therapy Be Personalized Based on Race? Ann. Pharmacother., March 1, 2006; 40(3): 550 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Podgoreanu and D. A. Schwinn New Paradigms in Cardiovascular Medicine: Emerging Technologies and Practices: Perioperative Genomics J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1965 - 1977. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Page, H. Reich, J. Zhou, V. Lai, D. C. Cattran, J. W. Scholey, and J. A. Miller Endothelial Nitric Oxide Synthase Gene/Gender Interactions and the Renal Hemodynamic Response to Angiotensin II J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3053 - 3060. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Antoniades, D. Tousoulis, C. Vasiliadou, C. Pitsavos, C. Chrysochoou, D. Panagiotakos, C. Tentolouris, K. Marinou, N. Koumallos, and C. Stefanadis Genetic Polymorphism on Endothelial Nitric Oxide Synthase Affects Endothelial Activation and Inflammatory Response During the Acute Phase of Myocardial Infarction J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1101 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Malhotra, J. Poole, H. Davis, Y. Dong, J. Pollock, H. Snieder, and F. Treiber Effects of NOS3 Glu298Asp Polymorphism on Hemodynamic Reactivity to Stress: Influences of Ethnicity and Obesity Hypertension, December 1, 2004; 44(6): 866 - 871. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cook, O. Hugli, M. Egli, B. Menard, S. Thalmann, C. Sartori, C. Perrin, P. Nicod, B. Thorens, P. Vollenweider, et al. Partial Gene Deletion of Endothelial Nitric Oxide Synthase Predisposes to Exaggerated High-Fat Diet--Induced Insulin Resistance and Arterial Hypertension Diabetes, August 1, 2004; 53(8): 2067 - 2072. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Podgoreanu and D. A. Schwinn Genomics and the circulation Br. J. Anaesth., July 1, 2004; 93(1): 140 - 148. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Paradossi, E. Ciofini, A. Clerico, N. Botto, A. Biagini, and M. G. Colombo Endothelial Function and Carotid Intima-Media Thickness in Young Healthy Subjects Among Endothelial Nitric Oxide Synthase Glu298->Asp and T-786->C Polymorphisms Stroke, June 1, 2004; 35(6): 1305 - 1309. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Casas, L. E. Bautista, S. E. Humphries, and A. D. Hingorani Endothelial Nitric Oxide Synthase Genotype and Ischemic Heart Disease: Meta-Analysis of 26 Studies Involving 23028 Subjects Circulation, March 23, 2004; 109(11): 1359 - 1365. [Abstract] [Full Text] [PDF] |
||||
![]() |
J U Kim, H K Chang, S S Lee, J W Kim, K T Kim, S W Lee, and W T Chung Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease and rheumatic diseases with vasculitis Ann Rheum Dis, November 1, 2003; 62(11): 1083 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Brown, L. A.J. Kluijtmans, I. S. Young, J. Woodside, J. W.G. Yarnell, D. McMaster, L. Murray, A. E. Evans, C. A. Boreham, H. McNulty, et al. Genetic Evidence That Nitric Oxide Modulates Homocysteine: The NOS3 894TT Genotype Is a Risk Factor for Hyperhomocystenemia Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1014 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N Van Vliet, L. L Chafe, and J.-P. Montani Characteristics of 24 h Telemetered Blood Pressure in eNOS-Knockout and C57Bl/6J Control Mice J. Physiol., May 15, 2003; 549(1): 313 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. McNamara, R. Holubkov, L. Postava, R. Ramani, K. Janosko, M. Mathier, G. A. MacGowan, S. Murali, A. M. Feldman, and B. London Effect of the Asp298 Variant of Endothelial Nitric Oxide Synthase on Survival for Patients With Congestive Heart Failure Circulation, April 1, 2003; 107(12): 1598 - 1602. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Paolo Rossi, M. Cesari, M. Zanchetta, S. Colonna, G. Maiolino, L. Pedon, M. Cavallin, P. Maiolino, and A. C. Pessina The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study J. Am. Coll. Cardiol., March 19, 2003; 41(6): 930 - 937. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Rossi, S. Taddei, A. Virdis, M. Cavallin, L. Ghiadoni, S. Favilla, D. Versari, I. Sudano, A. C. Pessina, and A. Salvetti The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients J. Am. Coll. Cardiol., March 19, 2003; 41(6): 938 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Loscalzo Functional polymorphisms in a candidate gene for atherothrombosis: Unraveling the complex fabric of a polygenic phenotype J. Am. Coll. Cardiol., March 19, 2003; 41(6): 946 - 948. [Full Text] [PDF] |
||||
![]() |
E. Noiri, H. Satoh, J.-i. Taguchi, S. V. Brodsky, A. Nakao, Y. Ogawa, S. Nishijima, T. Yokomizo, K. Tokunaga, and T. Fujita Association of eNOS Glu298Asp Polymorphism With End-Stage Renal Disease Hypertension, October 1, 2002; 40(4): 535 - 540. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Komatsu, T. Kawagishi, M. Emoto, T. Shoji, A. Yamada, K. Sato, M. Hosoi, and Y. Nishizawa ecNOS gene polymorphism is associated with endothelium-dependent vasodilation in Type 2 diabetes Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H557 - H561. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.P.M. Leeson, A.D. Hingorani, M.J. Mullen, N. Jeerooburkhan, M. Kattenhorn, T.J. Cole, D.P.R. Muller, A. Lucas, S.E. Humphries, and J.E. Deanfield Glu298Asp Endothelial Nitric Oxide Synthase Gene Polymorphism Interacts With Environmental and Dietary Factors to Influence Endothelial Function Circ. Res., June 14, 2002; 90(11): 1153 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
M G Colombo, M G Andreassi, U Paradossi, N Botto, S Manfredi, S Masetti, G Rossi, A Clerico, and A Biagini Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298->Asp polymorphism) to the presence, extent, and severity of coronary artery disease Heart, June 1, 2002; 87(6): 525 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Savvidou, P. J.T. Vallance, K. H. Nicolaides, and A. D. Hingorani Endothelial Nitric Oxide Synthase Gene Polymorphism and Maternal Vascular Adaptation to Pregnancy Hypertension, December 1, 2001; 38(6): 1289 - 1293. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Naber, D. Baumgart, C. Altmann, W. Siffert, R. Erbel, and G. Heusch eNOS 894T allele and coronary blood flow at rest and during adenosine-induced hyperemia Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H1908 - H1912. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Heusch, R. Erbel, and W. Siffert Genetic determinants of coronary vasomotor tone in humans Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1465 - H1468. [Full Text] [PDF] |
||||
![]() |
M. Scherrer-Crosbie, R. Ullrich, K. D. Bloch, H. Nakajima, B. Nasseri, H. T. Aretz, M. L. Lindsey, A.-C. Vancon, P. L. Huang, R. T. Lee, et al. Endothelial Nitric Oxide Synthase Limits Left Ventricular Remodeling After Myocardial Infarction in Mice Circulation, September 11, 2001; 104(11): 1286 - 1291. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lembo, N. De Luca, C. Battagli, G. Iovino, A. Aretini, M. Musicco, G. Frati, F. Pompeo, C. Vecchione., and B. Trimarco A Common Variant of Endothelial Nitric Oxide Synthase (Glu298Asp) Is an Independent Risk Factor for Carotid Atherosclerosis Stroke, March 1, 2001; 32(3): 735 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Rankinen, T. Rice, L. Perusse, Y. C. Chagnon, J. Gagnon, A. S. Leon, J. S. Skinner, J. H. Wilmore, D. C. Rao, and C. Bouchard NOS3 Glu298Asp Genotype and Blood Pressure Response to Endurance Training : The HERITAGE Family Study Hypertension, November 1, 2000; 36(5): 885 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Elbaz, O. Poirier, T. Moulin, F. Chedru, F. Cambien, and P. Amarenco Association Between the Glu298Asp Polymorphism in the Endothelial Constitutive Nitric Oxide Synthase Gene and Brain Infarction Stroke, July 1, 2000; 31(7): 1634 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.E Safar, C. Thuilliez, V Richard, and A Benetos Pressure-independent contribution of sodium to large artery structure and function in hypertension Cardiovasc Res, May 1, 2000; 46(2): 269 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Busse and I. Fleming A critical look at cardiovascular translational research Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H1655 - H1660. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |